PHASE-I STUDY OF TRICYCLIC NUCLEOSIDE PHOSPHATE

  • 1 January 1983
    • journal article
    • research article
    • Vol. 67  (2) , 159-162
Abstract
A phase I study of tricyclic nucleoside phosphate [NSC-154020] was conducted in 20 adults with advanced cancer. Tricyclic nucleoside phosphate was given as an i.v. infusion over 15 min once every 3 wk; the doses ranged from 25-350 mg/m2. Beginning at a dose of 250 mg/m2, hyperglycemia and elevation of hepatocellular enzymes were observed. At a dose of 350 mg/m2, 2 patients developed irreversible liver damage. Patients at all dose levels experienced reduction in serum P. Reduction of serum Ca was noted only with the 2 highest doses. Nausea and vomiting occurred occasionally. Myelosuppression was not a prominent toxic effect. No major therapeutic responses were noted. Further clinical trials employing this schedule are probably not warranted.